An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months

Trial Profile

An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Mar 2014 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top